PleoPharma
View On Demand

Legalized Marijuana And The Challenges of Cannabis Addiction

About the Event


For most of the tens of millions of people who regularly use cannabis, it’s no different than enjoying a glass of wine after work.

Last year, however, 14.2 million people were diagnosed with cannabis use disorder and nearly 900,000 people were treated for cannabis addiction. For those who want to quit, the withdrawal symptoms can be as powerful as those from opioids, causing severe emotional, psychiatric, and physical illness. It’s an issue that is rarely discussed as more states have moved to legalization.

Our Panel On This Topic Includes:

  • Tommy Thompson: Former Governor of Wisconsin and HHS Secretary during the Bush administration, the department responsible for federal drug policy.
  • Dr. Ginger Constantine: CEO and Co-founder of PleoPharma, a development stage pharmaceutical company creating a treatment for Cannabis Withdrawal Syndrome

Join our webinar to hear these experts discuss the growing public health issue of cannabis addiction and what can be done to help those who want to quit.

View On-Demand


SHARE THIS EVENT
Share on facebook
Share on twitter
Share on linkedin

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.